Clinical Experience with Daptomycin for the Treatment of Gram-positive Infections in Children and Adolescents.

ABSTRACT:

Background

This subgroup analysis of the European Cubicin Outcomes Registry Experience evaluated the safety and effectiveness of daptomycin in children and adolescent patients (<18 years).

Methods

Clinical outcomes at the end of therapy were assessed as success (cured or improved), failure or nonevaluable. Safety was assessed for up to 30 days post treatment.

Results

Eighty-one children and adolescent patients were included in this study. The most common primary infections were bacteremia (19.8%), complicated skin and soft-tissue infection (18.5%), osteomyelitis (13.6%), endocarditis (12.3%), foreign body/prosthetic infection (12.3%), uncomplicated skin and soft-tissue infection (9.9%) and other (13.6%). Daptomycin doses ranged from 4 to >10 mg/kg/day. Median duration

SUBMITTER: Syriopoulou V 

PROVIDER: S-EPMC4830747 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature